Back to top
more

Catalent (CTLT)

(Delayed Data from NYSE)

$55.52 USD

55.52
1,151,777

-0.28 (-0.50%)

Updated May 14, 2024 04:00 PM ET

After-Market: $55.50 -0.02 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Looking for a Growth Stock? Why It is Time to Focus on Catalent (CTLT)

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).

Pacira (PCRX) Gets European Commission Approval for Exparel

The EC approves Pacira's (PCRX) Exparel for treating post-operative pain in adults and as a field block for treating somatic post-operative pain from small- to medium-sized surgical wounds in adults.

Aerie (AERI) Gets Positive CHMP Opinion for Roclanda in EU

Aerie (AERI) receives positive CHMP opinion for Roclanda for reduction of elevated intraocular pressure in adult patients.

Zoetis (ZTS) Librela Gets Marketing Authorization in Europe

Zoetis (ZTS) gets marketing authorization for Librela, for monthly alleviation of osteoarthritis pain in dogs.

Catalent (CTLT) Q1 Earnings and Revenues Top Estimates

Catalent (CTLT) delivered earnings and revenue surprises of 13.16% and 4.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates

United Therapeutics' (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.

AcelRx (ACRX) Looks Good: Stock Adds 5.3% in Session

AcelRx (ACRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Akebia Therapeutics (AKBA) Looks Good: Stock Adds 6.7% in Session

Akebia Therapeutics (AKBA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Ironwood to End IW-3718 Development After Study Failure

Ironwood's (IRWD) pipeline candidate, IW-3718, fails to meet primary endpoint in a phase III study evaluating it in patients with refractory GERD.

Endo (ENDP) Surges: Stock Moves 8.4% Higher

Endo (ENDP) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Revolution Medicines (RVMD) Looks Good: Stock Adds 6.9% in Session

Revolution Medicines (RVMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Spectrum Pharmaceuticals (SPPI) Jumps: Stock Rises 7%

Spectrum Pharmaceuticals (SPPI) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.

Vaxart (VXRT) Surges: Stock Moves 8.1% Higher

Vaxart (VXRT) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Champions Oncology (CSBR) Catches Eye: Stock Jumps 9.2%

Champions Oncology (CSBR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Marinus Pharmaceuticals (MRNS) Soars: Stock Adds 5.5% in Session

Marinus Pharmaceuticals (MRNS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

The Zacks Analyst Blog Highlights: Etsy, Generac, Catalent, Fortune Brands Home & Security and Wayfair

The Zacks Analyst Blog Highlights: Etsy, Generac, Catalent, Fortune Brands Home & Security and Wayfair

Sage Therapeutics (SAGE) in Focus: Stock Moves 5.1% Higher

Sage Therapeutics (SAGE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Nalak Das headshot

6 Top Stocks That Turned Large Cap From Mid Cap Amid Pandemic

In the due course of the S&P 400 Index's fabulous performance in the past five months, several mid-cap stocks have become large caps. We have selected six of these that carry a favorable Zacks Rank.

Tirthankar Chakraborty headshot

New Strong Buy Stocks For September 11th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Exelixis Inks a Couple of Deals to Develop Novel ADCs for Cancer

Exelixis (EXEL) signs a collaboration agreement with private biotech NBE-Therapeutics for developing novel antibody-drug conjugates (ADCS) to address cancer. It also inks a similar deal with Catalent.

Merck Announces Detailed Data on Late-Stage Cough Candidate

Merck (MRK) announced detailed data from two pivotal studies evaluating gefapixant in patients with refractory or unexplained chronic cough.

Radius Completes Enrollment in Phase III Osteoporosis Study

Radius (RDUS) completes enrollment in its phase III study assessing a wearable abaloparatide-transdermal patch in the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Is Catalent (CTLT) a Great Growth Stock?

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).

Is Catalent (CTLT) a Great Growth Stock?

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).

David Borun headshot

High-Flying Equities Stumble, but Remain Near All-Time Highs

Technology stocks slip modestly as investors reassess valuations after an historic rally off March lows.